paclitaxel + pictilisib

The combination of paclitaxel and pictilisib is a therapeutic approach that has been studied for the treatment of breast cancer. Pictilisib (GDC-0941) is a pan-phosphatidylinositol 3-kinase (PI3K) inhibitor that targets the PI3K pathway, which is frequently activated in hormone receptor-positive breast cancers[1][2]. Paclitaxel is a well-established chemotherapeutic agent that is commonly used in breast cancer treatment. ## Clinical Development This combination has been evaluated in clinical trials, including a phase Ib study (NCT00960960) that assessed pictilisib plus paclitaxel with and without bevacizumab or trastuzumab, or in combination with letrozole, in patients with locally recurrent or metastatic breast cancer[1]. The study established the maximum tolerated dose (MTD) and recommended phase II doses for pictilisib. Another significant trial was the PEGGY study (NCT01740336), a randomized, placebo-controlled phase II trial that examined whether pictilisib (260 mg daily on days 1-5 every week) augments the anti-tumor activity of paclitaxel (90 mg/m² weekly for 3 weeks in every 28-day cycle) in patients with hormone receptor-positive, HER2-negative locally recurrent or metastatic breast cancer[2]. ## Efficacy and Safety In the phase Ib study, the combination showed some promising activity with 2 (3.4%) patients experiencing complete responses and 17 (29.3%) patients having partial responses[1]. The study concluded that combining pictilisib with paclitaxel had a manageable safety profile and demonstrated antitumor activity. However, the PEGGY phase II trial did not meet its primary endpoint. In the intention-to-treat population, the median progression-free survival was 8.2 months with pictilisib versus 7.8 months with placebo (hazard ratio for progression or death, 0.95; 95% confidence interval 0.62-1.46; P = 0.83)[2]. Similarly, in patients with PIK3CA-mutated tumors, there was no significant benefit from adding pictilisib to paclitaxel. The safety profile of pictilisib was consistent with previous reports, with no new safety signals identified. However, the proportions of patients with grade ≥3 adverse events, serious adverse events, and dose reductions/discontinuations due to adverse events were higher with pictilisib compared to placebo[2]. ## Mechanism of Action The combination leverages complementary mechanisms: pictilisib inhibits the PI3K pathway, which is often aberrantly activated in breast cancer, particularly in hormone receptor-positive tumors with PIK3CA mutations. Paclitaxel works by stabilizing microtubules, preventing cell division. The preclinical rationale suggested that pictilisib might potentiate the effect of taxanes like paclitaxel, potentially benefiting patients regardless of PI3K pathway activation status[2]. Importantly, pharmacokinetic analyses from the phase Ib study showed no drug-drug interaction between pictilisib and paclitaxel[1], suggesting that the combination could be administered without dose adjustments due to pharmacokinetic concerns. As of March 2025, pictilisib's highest global R&D status is Phase 2[4], indicating that development of this agent, including its combination with paclitaxel, has not yet progressed to Phase 3 trials or approval.